NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
08 Nov 2013

AM-Pharma presents positive data from recAP preclinical study at ASN meeting

Bunnik, The Netherlands; Atlanta, GA, 8 November 2013. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, today presents preclinical data on its drug candidate recAP in an Acute Kidney Injury (AKI) setting, at the American Society of Nephrology (ASN) meeting Kidney Week in Atlanta, GA, USA.
05 Nov 2013

TiGenix Business Update & Financial Highlights for Q3 of 2013

Leuven (BELGIUM) – November 5, 2013 –TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, gives an update of its business activities and provides the financial highlights for the third quarter ending September 30, 2013.
CVRx® Closes $12 Million Additional Financing<
30 Oct 2013

CVRx® Closes $12 Million Additional Financing

Minneapolis – October 30, 2013 – CVRx, Inc., a privately held medical device company, has closed on an additional $12 million under its Series F financing.
23 Sep 2013

AM-Pharma returns to clinic with Phase I trial of new recombinant human Alkaline Phosphatase to treat Acute Kidney Injury

Bunnik, The Netherlands, 23 September 2013. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recombinanthuman Alkaline Phosphatase (AP) for inflammatory indications is pleased to announce that the first subjects have entered a Phase I trial of its recombinant AP (recAP) to treat Acute Kidney Injury (AKI).
13 Sep 2013

St. Jude Medical Acquires Endosense

St. Jude Medical adds ablation catheter with contact-force measurement to its industry-leading atrial fibrillation portfolio and accelerates U.S. timeline for AF ablation indication
18 Jul 2013

TiGenix Raises EUR 6.5 million in Private Placement

Leuven, Belgium – July 18, 2013, 20:00h – TiGenix NV (Euronext Brussels: TIG) announces today that it has raised EUR 6.5 million through a private placement via the accelerated bookbuilding procedure announced on July 17, 2013 after the market closed.
17 Jul 2013

TiGenix to Raise Capital via a Private Placement of New Ordinary Shares

Leuven, Belgium – July 17, 2013, 18:00h – TiGenix NV (Euronext Brussels: TIG) today announced the launch of a private placement of new ordinary shares for a targeted amount of EUR 5 million.
19 Jun 2013

STAT-Diagnostica Names Gérard Vaillant as Board Chairman

BARCELONA – June 19, 2013 – Medical diagnostics company STAT-Diagnostica has appointed Gérard Vaillant as chairman of the company’s board of directors.
10 Jun 2013

MedLumics appoints Dr. Wolfgang Reim as Independent Director

Madrid, 10th June 2013. MedLumics, a medical imaging company specializing in advanced optical coherence tomography (OCT) technology, has announced the appointment of the industry expert Wolfgang Reim as Independent Director for its board.
14 May 2013

TiGenix Business Update & Financial Highlights for Q1 of 2013

Leuven (BELGIUM) – May 14, 2013 –TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, gives an update of its business activities and provides the financial highlights for the first quarter ending March 31, 2013.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.